Table 1.
Patient characteristics (n=50)
| Patient characteristics | n (%) |
|---|---|
| Age (years) | |
| ≤60 | 27 (54%) |
| >60 | 23 (46%) |
| Sex | |
| Men | 14 (28%) |
| Women | 36 (72%) |
| ECOG performance status | |
| 0-1 | 31 (62%) |
| 2 | 19 (38%) |
| Previous lines of therapies for recurrent or metastatic disease | |
| ≤2 | 23 (46%) |
| >2 | 27 (54%) |
| Previous therapeutic regimen | |
| Including taxanes | 38 (76%) |
| Excluding taxanes | 12 (24%) |
| Trial regimen | |
| UTD1 monotherapy | 8 (16%) |
| Combination therapy | 42 (84%) |
| Metastatic sites | |
| ≤2 | 18 (36%) |
| >2 | 32 (64%) |
| Pathological type | |
| Adenocarcinoma | 38 (76%) |
| Squamous cell carcinoma | 8 (16%) |
| Sarcoma | 3 (6%) |
| Urothelial carcinoma | 1 (2%) |
| Tumor entities | |
| Breast cancer | 20 (40%) |
| Gynecological cancers | 11 (22%) |
| Gastrointestinal cancers | 8 (16%) |
| Lung cancer | 6 (12%) |
| Other solid tumors | 5 (10%) |
ECOG, Eastern Cooperative Oncology Group; UTD1, utidelone.